Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$103.2b

Regeneron Pharmaceuticals Valuation

Is REGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REGN ($959.92) is trading below our estimate of fair value ($1789.18)

Significantly Below Fair Value: REGN is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGN?

Other financial metrics that can be useful for relative valuation.

REGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.8x
Enterprise Value/EBITDA19.3x
PEG Ratio2.7x

Price to Earnings Ratio vs Peers

How does REGN's PE Ratio compare to its peers?

The above table shows the PE ratio for REGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.1x
GILD Gilead Sciences
16.1x6.5%US$91.3b
VRTX Vertex Pharmaceuticals
29.4x11.2%US$106.3b
AMGN Amgen
21.6x9.2%US$145.2b
ABBV AbbVie
65.4x23.5%US$315.3b
REGN Regeneron Pharmaceuticals
26.1x9.5%US$103.2b

Price-To-Earnings vs Peers: REGN is good value based on its Price-To-Earnings Ratio (26.1x) compared to the peer average (33.1x).


Price to Earnings Ratio vs Industry

How does REGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: REGN is expensive based on its Price-To-Earnings Ratio (26.1x) compared to the US Biotechs industry average (13.6x).


Price to Earnings Ratio vs Fair Ratio

What is REGN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.1x
Fair PE Ratio29.5x

Price-To-Earnings vs Fair Ratio: REGN is good value based on its Price-To-Earnings Ratio (26.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$959.92
US$1,017.22
+6.0%
11.6%US$1,184.00US$710.00n/a25
Mar ’25US$982.82
US$1,009.93
+2.8%
11.8%US$1,184.00US$710.00n/a23
Feb ’25US$957.78
US$968.35
+1.1%
11.8%US$1,125.00US$710.00n/a24
Jan ’25US$878.29
US$919.76
+4.7%
11.6%US$1,125.00US$700.00n/a24
Dec ’24US$814.86
US$908.57
+11.5%
10.7%US$1,066.00US$680.00n/a25
Nov ’24US$791.27
US$902.36
+14.0%
10.6%US$1,064.00US$680.00n/a23
Oct ’24US$822.96
US$898.87
+9.2%
10.5%US$1,050.00US$680.00n/a23
Sep ’24US$831.63
US$895.61
+7.7%
10.8%US$1,050.00US$665.00n/a23
Aug ’24US$739.07
US$857.78
+16.1%
10.6%US$1,045.00US$650.00n/a23
Jul ’24US$718.54
US$862.87
+20.1%
11.7%US$1,045.00US$650.00n/a23
Jun ’24US$731.17
US$883.78
+20.9%
10.9%US$1,050.00US$650.00n/a23
May ’24US$806.72
US$878.61
+8.9%
10.5%US$1,040.00US$650.00n/a23
Apr ’24US$821.67
US$871.83
+6.1%
10.9%US$1,040.00US$650.00n/a23
Mar ’24US$770.44
US$830.78
+7.8%
12.2%US$1,011.00US$605.00US$982.8223
Feb ’24US$758.00
US$806.78
+6.4%
12.5%US$1,023.00US$605.00US$957.7823
Jan ’24US$721.49
US$801.04
+11.0%
13.0%US$1,027.00US$595.00US$878.2923
Dec ’23US$761.24
US$795.83
+4.5%
13.3%US$1,027.00US$575.00US$814.8623
Nov ’23US$759.91
US$780.78
+2.7%
13.4%US$1,025.00US$575.00US$791.2723
Oct ’23US$688.87
US$749.00
+8.7%
11.2%US$925.00US$575.00US$822.9622
Sep ’23US$600.63
US$676.32
+12.6%
10.7%US$796.00US$536.00US$831.6322
Aug ’23US$576.68
US$674.05
+16.9%
10.5%US$790.00US$536.00US$739.0722
Jul ’23US$595.40
US$679.24
+14.1%
11.5%US$790.00US$536.00US$718.5421
Jun ’23US$658.92
US$691.67
+5.0%
9.3%US$790.00US$565.00US$731.1721
May ’23US$659.11
US$685.40
+4.0%
10.4%US$781.00US$565.00US$806.7220
Apr ’23US$694.83
US$689.71
-0.7%
11.2%US$843.00US$570.00US$821.6721
Mar ’23US$607.03
US$691.91
+14.0%
11.3%US$843.00US$560.00US$770.4422

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.